An international, multi-center, open-label, 2-arm phase III trial of adjuvant bevacizumab in triple-negative breast cancer
BEATRICE
Clinical Trial Program
An international, multi-center, open-label, 2-arm phase III trial of adjuvant bevacizumab in triple-negative breast cancer
Phase III
Status
Finished
Tumour subtype:
TNBC
Scenario
Adyuvante
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
David Cameron, MD (Professor of Oncology at Edinburgh University)
Sites
